Comparing infusion timing for lung cancer immunotherapy before surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II or III non-small cell lung cancer that can be removed with surgery.
- You have not had prior chemotherapy, immunotherapy, or other cancer treatment for this lung cancer.
- Your general health is good enough for surgery (ECOG score 0 or 1).
- You do not have specific gene mutations (EGFR, ALK/ROS1) or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving immunotherapy at different times around surgery for stage II-IIIA non-small cell lung cancer. The goal is to find the best time to use this treatment to improve outcomes.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
Hear when a new Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.